Access Statistics for Izabela Jelovac

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Basic, applied research, and price negotiation for new drugs 0 0 0 0 0 0 1 17
Comparing Organizational Structures in Health Services 0 0 0 0 0 0 1 2,389
Comparing approval procedures for new drugs 0 0 0 0 0 0 0 23
Comparing organizational structures in health services 0 0 0 0 0 0 1 1
Demand versus Supply Side Cost-Sharing: Patients’ preferences 0 0 0 0 0 0 0 18
Demand versus Supply Side Cost-Sharing: The users' perspective 0 0 0 0 0 0 0 21
Demand versus Supply Side Cost-Sharing: The users' perspective 0 0 0 0 0 0 0 15
Des « Nobels » de sciences économiques au service des systèmes de santé 0 0 0 0 0 0 0 0
Des « Nobels » de sciences économiques au service des systèmes de santé 0 0 0 0 0 0 1 13
Do free-of-charge public health services impede cost recovery policies in Khartoum state, Sudan? 0 0 0 7 0 0 0 90
Drug approval decision times, international reference pricing and access to new drugs 0 0 0 0 0 0 1 20
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 0 0 4 36
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 11 0 0 0 56
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 0 0 0 34
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 1 1 8 0 3 4 55
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 0 0 1 32
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 0 0 0 28
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 0 0 1 33
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 1 1 2 30
Drug launch timing and international reference pricing 0 0 0 17 0 0 1 89
Drug launch timing and international reference pricing 0 0 0 0 0 0 1 51
Drug launch timing and international reference pricing 0 0 0 0 0 0 0 21
Drug launch timing and international reference pricing 0 0 0 0 0 0 1 25
Drug launch timing and international reference pricing 0 0 0 34 0 0 1 66
Drug launch timing and international reference pricing 0 0 0 0 0 0 0 21
Drug launch timing and international reference pricing 0 0 0 0 0 0 0 45
Enjeux tarifaires de la médecine génomique 0 0 0 0 0 0 1 18
External Reference Pricing and Sequential Launching of Drugs 0 0 0 0 0 1 1 35
External referencing and pharmaceutical price negotiation 0 0 1 10 0 0 1 39
External referencing and pharmaceutical price negotiation 0 0 2 152 0 0 3 459
External referencing and pharmaceutical price negotiation 0 0 0 0 0 0 0 27
GPs’ Payment Contracts and their Referral Policy 0 0 0 14 0 1 1 101
GPs’ payment contracts and their referral practice 0 0 0 0 0 0 0 0
Health Services: Incentives and Access. Keynote speech 0 0 0 0 0 0 0 20
Health services: Incentives and access 0 0 0 0 0 0 1 18
Healthcare providers’ payments with personalized medicine 0 0 0 0 0 0 0 9
Household health-seeking behaviour in Khartoum, Sudan: The willingness to pay for public health services if these services are of good quality 0 0 0 0 0 0 2 3
How Should Donors Give Foreign Aid? Project Aidversus Budget Support 1 1 1 63 1 1 4 374
How should donors give foreign aid ? A theoretical comparison of aid modalities 0 0 0 0 0 0 0 17
How should donors give foreign aid? Project aid versus budget support 0 0 0 111 0 0 1 277
How should donors give foreign aid? Project aid versus budget support 0 1 1 171 0 1 3 643
Incentives to patients versus incentives to health care providers: The users' perspective 0 0 0 0 0 0 0 25
Incentives to patients versus incentives to health care providers: The users' perspective 0 0 0 17 0 0 0 40
Incentives to patients versus incentives to health care providers: The users' perspective 0 0 0 0 0 0 0 34
Incentives to patients versus incentives to health care providers: The users’ perspective 0 0 0 27 0 0 0 61
La Médecine personnalisée 0 0 0 0 0 0 1 32
Médecine personnalisée et prix des médicaments 0 0 0 0 0 0 1 21
On the relationship between the negociated price of pharmaceuticals and the patients' co-payment 0 0 0 0 0 0 2 63
On the relationship between the negociated price of pharmaceuticals and the patients' co-payment 0 0 0 0 1 1 4 34
Payment mechanism and GP self-selection: capitation versus fee for service 0 0 0 0 0 1 5 54
Perception du lien entre mode de rémunération et comportement des médecins 0 0 0 0 0 0 0 27
Perception du lien entre mode de rémunération et comportement des médecins 0 0 0 0 0 0 0 29
Personalized medicine and drug prices 0 0 0 0 0 0 0 42
Physicians Balance Billing, Supplemental Insurance and Access to Health Care 0 0 0 0 0 0 0 43
Physicians Balance Billing, Supplemental Insurance and Access to Health Care 0 0 0 0 0 0 0 40
Physicians Balance Billing, Supplemental Insurance and Access to Health Care 0 0 0 0 0 0 4 28
Physicians Balance Billing, Supplemental Insurance and Access to Health Care 0 0 0 0 0 0 0 46
Physicians self selection of a payment mechanism: Capitation versus fee-for-service 0 1 1 30 1 2 6 286
Physicians self selection of a payment mechanism: Capitation versus fee-for-service 0 0 0 31 0 1 1 89
Physicians' Balance Billing, Fees Negotiations and Supplementary Insurance 0 0 0 0 0 0 0 12
Physicians' Balance Billing, Fees Negotiations and Supplementary Insurance 0 0 0 0 0 0 0 13
Physicians' Balance Billing, Fees Negotiations and Supplementary Insurance 0 0 0 0 0 0 0 11
Physicians' balance billing, supplemental insurance and access to health care 0 1 1 14 0 1 1 84
Physicians’ balance billing, supplemental insurance and access to health care 0 0 0 27 1 1 2 114
Physicians’ balance billing, supplemental insurance and access to health care 0 0 0 0 0 1 7 53
Preferences for Demand versus Supply Side Cost-Sharing 0 0 0 0 0 0 0 13
Pricing and Welfare Implications of Parallel Imports in the Pharmaceutical Industry 1 1 1 1 1 1 3 3
Pricing and Welfare of Parallel Imports in the Pharmaceutical Industry 0 0 0 165 0 0 1 443
Primary Care, Gatekeeping and Incentives 0 0 0 0 0 0 5 87
Regulation and Altruism 0 0 0 29 0 0 3 47
Regulation and Altruism 0 0 0 25 0 0 1 35
Regulation and altruism 0 0 0 9 0 0 1 35
Regulation and altruism 0 0 0 27 0 0 1 40
Research funding and price negotiation for new drugs 0 0 0 0 0 0 0 4
Research funding and price negotiation for new drugs 0 0 0 0 0 0 0 10
Research funding and price negotiation for new drugs 0 0 0 0 0 0 0 5
Research funding and price negotiation for new drugs 0 0 0 0 0 0 0 7
Research funding and price negotiation for new drugs 0 0 0 0 1 1 1 18
Research funding and price negotiation for new drugs 0 0 0 0 0 0 0 18
Research funding and price negotiation for new drugs 0 0 0 47 0 0 0 21
Research funding and price negotiation for new drugs 0 0 0 53 0 0 0 39
The pricing of physicians' services with distant medicine and health insurance 0 0 1 7 0 1 3 25
The pricing of physicians' services with distant medicine and health insurance 0 0 1 5 0 0 1 6
Treatment and referral decisions under different physician payment mechanisms 0 0 0 39 0 0 0 103
Total Working Papers 2 6 11 1,151 7 19 93 7,509


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Comparing approval procedures for new drugs 0 0 0 9 0 0 2 22
Comparing organizational structures in health services 0 0 1 125 0 0 2 363
Drug Launch Timing and International Reference Pricing 0 0 1 11 0 0 2 38
External referencing and pharmaceutical price negotiation 0 0 0 40 0 0 4 176
GPs' payment contracts and their referral practice 0 0 2 85 0 0 2 295
Household health-seeking behaviour in Khartoum, Sudan: The willingness to pay for public health services if these services are of good quality 0 0 0 34 0 0 4 133
How Should Donors Give Foreign Aid? A Theoretical Comparison of Aid Modalities 0 0 0 16 0 0 0 36
Incentives to patients versus incentives to health care providers: The users' perspective 0 0 1 5 0 0 1 22
On the relationship between the negotiated prices of pharmaceuticals and the patients' co-payment 0 0 2 39 0 1 11 121
Payment mechanism and GP self-selection: capitation versus fee for service 0 1 2 20 0 1 3 219
Physicians' payment contracts, treatment decisions and diagnosis accuracy 0 0 0 2 0 0 2 193
Physicians’ balance billing, supplemental insurance and access to health care 0 0 0 11 0 0 0 63
Pricing and Welfare Implications of Parallel Imports in the Pharmaceutical Industry 0 0 0 128 0 0 0 330
Regulation and altruism 0 0 0 0 0 0 0 19
Research funding and price negotiation for new drugs 0 1 1 4 0 1 3 33
Treatment and referral decisions under different physician payment mechanisms 0 0 0 19 0 1 3 109
Total Journal Articles 0 2 10 548 0 4 39 2,172


Statistics updated 2024-06-06